연구성과로 돌아가기
2022 연구성과 (74 / 280)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Satisfaction with permanent changes after cancer surgery: From personal satisfaction of gastric cancer survivors with post-gastrectomy weight loss | Background: This study assessed the personal satisfaction of gastric cancer survivors with post-gastrectomy weight loss. The responses were analyzed in relation to the actual weight status based on two general criteriadpreoperative weight and the World Health Organization (WHO) weight classi-ficationdas part of an attempt to identify patterns of satisfaction with weight loss.Methods: Survivors with significant postoperative weight loss (>= 8%) were identified among 1-and 5-year survivors, and were divided into obese/non-obese weight losers (WLs) based on the WHO defini-tion of obesity. For comparison, those with minimal weight change (not exceeding +/- 3%) at each time period were identified (non-WLs).The EORTC QLQ-C30 and-STO22 questionnaires were used to monitor quality of life (QoL). Responses to an item in the EORTC QLQ-STO22, inquiring about personal concerns with weight loss, were used to assess personal satisfaction with weight changes.Results: Except for the QoL disadvantages of non-obese WLs in anxiety (P = 0.011) of 1-year survivors and in emotional functioning (P = 0.039) of 5-year survivors, there was no significant difference in QoL changes between groups. Regarding personal satisfaction with decreased body weight, non-obese WLs continued to show dissatisfaction (P < 0.001) unlike obese WLs, who enjoyed satisfaction comparable to non-WLs long after surgery.Conclusion: Compared with non-obese WLs who expressed dissatisfaction with current weight, obese WLs were satisfied with their current weight several years after surgery. Patient satisfaction with surgical changes may depend on the availability of reasonable grounds that suggest a positive interpretation of surgically altered status.(c) 2022 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/). | Lee, Seung Soo; Chung, Ho Young; Kwon, Oh Kyoung | Kyungpook Natl Univ, Sch Med, Dept Surg, Daegu, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea; Kyungpook Natl Univ Hosp, Dept Surg, 130 Dongdeok Ro, Daegu 41944, South Korea | 54400392100; 56008255800; 26536109900 | hychung@knu.ac.kr; | ASIAN JOURNAL OF SURGERY | ASIAN J SURG | 1015-9584 | 0219-3108 | 45 | 12 | SCIE | SURGERY | 2022 | 3.5 | 17.6 | 0.83 | 2025-06-25 | 4 | 4 | Gastrectomy; Personal satisfaction; Quality of life; Stomach neoplasms; Weight loss | QUALITY-OF-LIFE; BODY-COMPOSITION; BARIATRIC SURGERY; CHALLENGE; PATTERNS; PATIENT | Gastrectomy; Personal satisfaction; Quality of life; Stomach neoplasms; Weight loss | Cancer Survivors; Gastrectomy; Humans; Obesity; Personal Satisfaction; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Survivors; Weight Loss; body weight loss; cancer survivor; gastrectomy; human; obesity; quality of life; questionnaire; satisfaction; stomach tumor; survivor | English | 2022 | 2022-12 | 10.1016/j.asjsur.2021.11.067 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia | Alopecia or baldness is a common diagnosis in clinical practice. Alopecia can be scarring or non-scarring, diffuse or patchy. The most prevalent type of alopecia is non-scarring alopecia, with the majority of cases being androgenetic alopecia (AGA) or alopecia areata (AA). AGA is traditionally treated with minoxidil and finasteride, while AA is treated with immune modulators; however, both treatments have significant downsides. These drawbacks compel us to explore regenerative therapies that are relatively devoid of adverse effects. A thorough literature review was conducted to explore the existing proven and experimental regenerative treatment modalities in non-scarring alopecia. Multiple treatment options compelled us to classify them into growth factor-rich and stem cell-rich. The growth factor-rich group included platelet-rich plasma, stem cell-conditioned medium, exosomes and placental extract whereas adult stem cells (adipose-derived stem cell-nano fat and stromal vascular fraction; bone marrow stem cell and hair follicle stem cells) and perinatal stem cells (umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs), Wharton jelly-derived MSCs (WJ-MSCs), amniotic fluid-derived MSCs (AF-MSCs), and placental MSCs) were grouped into the stem cell-rich group. Because of its regenerative and proliferative capabilities, MSC lies at the heart of regenerative cellular treatment for hair restoration. A literature review revealed that both adult and perinatal MSCs are successful as a mesotherapy for hair regrowth. However, there is a lack of standardization in terms of preparation, dose, and route of administration. To better understand the source and mode of action of regenerative cellular therapies in hair restoration, we have proposed the "A La Mode Classification". In addition, available evidence-based cellular treatments for hair regrowth have been thoroughly described. | Anudeep, Talagavadi Channaiah; Jeyaraman, Madhan; Muthu, Sathish; Rajendran, Ramya Lakshmi; Gangadaran, Prakash; Mishra, Prabhu Chandra; Sharma, Shilpa; Jha, Saurabh Kumar; Ahn, Byeong-Cheol | Topiwalla Natl Med Coll, Dept Plast Surg, Mumbai 400008, Maharashtra, India; BYL Nair Charitable Hosp, Mumbai 400008, Maharashtra, India; Sharda Univ, Sch Engn & Technol, Dept Biotechnol, Greater Noida 201310, India; A La Mode Esthet Studio, Mysuru 570011, Karnataka, India; Int Assoc Stem Cell & Regenerat Med IASRM, New Delhi 110092, India; Dr MGR Educ & Res Inst, Dept Orthopaed, Fac Med, Sri Lalithambigai Med Coll & Hosp, Chennai 600095, Tamil Nadu, India; Govt Med Coll & Hosp, Dept Orthopaed, Dindigul 624304, India; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Nucl Med, Daegu 41944, South Korea; Kyungpook Natl Univ, Sch Med, Dept Biomed Sci, Daegu 41944, South Korea; All India Inst Med Sci, Dept Paediat Surg, New Delhi 110029, India | Gangadaran, Prakash/AAV-3102-2021; Jha, Dr. Saurabh/ACC-9874-2022; Rajendran, Ramya/AAV-6338-2021; Muthu, Sathish/G-5756-2018; Jeyaraman, Madhan/ABB-8464-2020; Sharma, Shilpa/T-6420-2019 | 57216919866; 57216926503; 57217850874; 57195318729; 54393130400; 57219332018; 55491666000; 56425051500; 7202791511 | dranudeep@gmail.com;madhanjeyaraman@gmail.com;drsathishmuthu@gmail.com;ramyag@knu.ac.kr;prakashg@knu.ac.kr;info@iasrmglobal.org;drshilpas@gmail.com;saurabh.jha@sharda.ac.in;abc2000@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 3 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 1 | 2025-06-25 | 28 | 28 | alopecia; mesenchymal stem cells; regenerative therapy; cellular therapy | MESENCHYMAL STEM-CELLS; HUMAN AMNIOTIC-FLUID; HAIR FOLLICLE DEVELOPMENT; UMBILICAL-CORD STROMA; DERMAL PAPILLA CELLS; QUALITY-OF-LIFE; ANDROGENETIC ALOPECIA; IN-VIVO; GROWTH-FACTOR; BONE-MARROW | alopecia; cellular therapy; mesenchymal stem cells; regenerative therapy | finasteride; growth factor; minoxidil; placenta extract; adipose derived stem cell; adult stem cell; adverse event; alopecia; alopecia areata; amnion fluid; amniotic fluid stem cell; bone marrow mesenchymal stem cell; cell proliferation; cell regeneration; cell therapy; exosome; hair follicle cell; hair growth; hematopoietic stem cell; human; male type alopecia; mesenchymal stem cell; mesenchymal stroma cell; mesotherapy; non scarring alopecia; nonhuman; regenerative ability; Review; standardization; stromal vascular fraction; thrombocyte rich plasma; umbilical cord mesenchymal stem cell; Wharton jelly | English | 2022 | 2022-03 | 10.3390/pharmaceutics14030612 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Alternative Methotrexate Oral Formulation: Enhanced Aqueous Solubility, Bioavailability, Photostability, and Permeability | The poor aqueous solubility and/or permeability and thereby limited bioavailability largely restricts the pharmaco-therapeutic implications of potent anticancer drugs such as methotrexate (MTX). Furthermore, MTX's inherently unstable nature makes it difficult to develop a viable oral formulation. In this study we developed the spray-dried amorphous inclusion complexes of MTX with native beta-cyclodextrin (beta-CD) and its derivatives, namely HP-beta-CD, M-beta-CD, and DM-beta-CD to enhance the aqueous solubility, photostability, permeability, and oral bioavailability of MTX in rats. Our findings show that the 1:1 stoichiometry ratio of MTX and CDs improves the aqueous solubility, stability, and pharmacokinetic profiles of the drug, the better results being obtained particularly with DM-beta-CD as a host, which has a higher complexation ability with the drug compared to other beta-CDs. Specifically, the pharmacokinetic analysis demonstrated 2.20- and 3.29-fold increments in AUC and Cmax, respectively, in comparison to free MTX. Even though the absorptive permeability of MTX and MTX/DM-beta-CD inclusion complexes was similar, the efflux of the absorbed MTX from ICs was significantly lower compared to the free MTX (4.6- vs. 8.0-fold). Furthermore, the physicochemical characterization employing SEM, DSC, and PXRD confirmed the transformation of crystalline MTX to its amorphous state. In solution, H-1 NMR studies revealed that MTX embedded into the DM-beta-CD cavity resulting in both H-3 and H-5 chemical shifts implied the presence of intermolecular interaction between the drug and CD moiety. It was, therefore, evident that an MTX IC could be a successful oral formulation technique, preventing MTX degradation and enhancing its pharmacologically relevant properties. | Giri, Bhupendra Raj; Yang, Hyun Seok; Song, Im-Sook; Choi, Han-Gon; Cho, Jung Hyun; Kim, Dong Wuk | Kyungpook Natl Univ, BK21 FOUR Community Based Intelligent Novel Drug, Vessel Organ Interact Res Ctr VOICE, Res Inst Pharmaceut Sci,Coll Pharm,MRC, Daegu 41566, South Korea; Univ Texas Austin, Coll Pharm, Div Mol Pharmaceut & Drug Delivery, Pharmaceut Engn & 3D Printing Labs PharmE3D, Austin, TX 78705 USA; Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Ansan 15588, South Korea | ; Choi, HanGon/E-5252-2017; Giri, Bhupendra/GRR-3256-2022 | 57210211620; 57949331800; 7201564500; 7404339910; 56009051800; 57193445049 | kojane7301@hanmi.co.kr;dkim17@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 10 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 1.28 | 2025-06-25 | 12 | 12 | inclusion complex; methotrexate; solubility; bioavailability; permeability; beta-cyclodextrin (beta-CD) | BETA-CYCLODEXTRIN; INCLUSION COMPLEX; DELIVERY; RELEASE | bioavailability; inclusion complex; methotrexate; permeability; solubility; β-cyclodextrin (β-CD) | beta cyclodextrin; drug carrier; methotrexate; animal experiment; area under the curve; Article; Caco-2 cell line; complex formation; controlled study; differential scanning calorimetry; drug absorption; drug bioavailability; drug delivery system; drug elimination; drug formulation; drug half life; drug penetration; drug solubility; drug stability; drug structure; human; human cell; male; maximum concentration; molecular interaction; nonhuman; particle size; photostability; plasma concentration-time curve; proton nuclear magnetic resonance; rat; scanning electron microscopy; spray drying; stoichiometry; time to maximum plasma concentration; X ray powder diffraction | English | 2022 | 2022-10 | 10.3390/pharmaceutics14102073 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Atorvastatin Enhances the Efficacy of Immune Checkpoint Therapy and Suppresses the Cellular and Extracellular Vesicle PD-L1 | According to clinical studies, statins improve the efficacy of programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockade therapy for breast cancer; however, the underlying mechanisms are unclear. Herein, we showed that atorvastatin (ATO) decreased the content of PD-L1 in extracellular vesicles (EVs) by reducing cellular PD-L1 expression and inhibiting EV secretion in breast cancer cells, thereby enhancing the efficacy of anti-PD-L1 therapy. ATO reduced EV secretion by regulating the Rab proteins involved in EV biogenesis and secretion. ATO-mediated inhibition of the Ras-activated MAPK signaling pathway downregulated PD-L1 expression. In addition, ATO strongly promoted antitumor efficacy by inducing T cell-mediated tumor destruction when combined with an anti-PD-L1 antibody. Moreover, suppression of EV PD-L1 by ATO improved the reactivity of anti-PD-L1 therapy by enhancing T-cell activity in draining lymph nodes of EMT6-bearing immunocompetent mice. Therefore, ATO is a potential therapeutic drug that improves antitumor immunity by inhibiting EV PD-L1, particularly in response to immune escape during cancer. | Choe, Eun-Ji; Lee, Chan-Hyeong; Bae, Ju-Hyun; Park, Ju-Mi; Park, Seong-Sik; Baek, Moon-Chang | Kyungpook Natl Univ, Exosome Convergence Res Ctr ECRC, Sch Med, Dept Mol Med,CMRI, Daegu 41944, South Korea | 57377017300; 57189904697; 57225046295; 57221984091; 57378111300; 7006013097 | mcbaek@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 8 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 3.94 | 2025-06-25 | 39 | 37 | statin; atorvastatin; extracellular vesicles; EV PD-L1; immunotherapy | MEVALONATE PATHWAY; PROSTATE-CANCER; LUNG-CANCER; STATIN USE; PRENYLATION; PITAVASTATIN; COMBINATION; EXPRESSION; RISK | atorvastatin; EV PD-L1; extracellular vesicles; immunotherapy; statin | atorvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; immune checkpoint inhibitor; mitogen activated protein kinase; programmed death 1 ligand 1; programmed death 1 ligand 1 antibody; Rab protein; unclassified drug; 4T1 cell line; animal cell; animal experiment; animal model; antigenic escape; antineoplastic activity; Article; biogenesis; breast cancer; cancer combination chemotherapy; cell vacuole; controlled study; cytotoxicity; down regulation; drug efficacy; drug potentiation; EMT6 cell line; exosome; female; human; human cell; immune response; MAPK signaling; MDA-MB-231 cell line; mouse; nonhuman; protein expression; T lymphocyte; tumor draining lymph node | English | 2022 | 2022-08 | 10.3390/pharmaceutics14081660 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Editorial Material | Blue Mold Rot Caused by Penicillium expansum on Polygonatum odoratum var. pluriflorum | Kim, D. -H.; Park, J. Y.; Choi, H. -W.; Choi, H. -R.; Lee, S. -H.; Hong, S. -B. | Kyungpook Natl Univ, Dept Food Sci & Biotechnol, Daegu 41566, South Korea; Rural Dev Adm, Int Technol Cooperat Div, Jeonju 54875, South Korea; Rural Dev Adm, Natl Inst Agr Sci, Crop Protect Div, Wonju 55365, South Korea; Rural Dev Adm, Natl Inst Agr Sci, Agr Microbiol Div, Wonju 55365, South Korea | Lee, Suheon/LIF-6888-2024 | 57994755300; 57848194500; 55890203000; 57847972300; 59056703200; 35198177100 | funguy@korea.kr; | PLANT DISEASE | PLANT DIS | 0191-2917 | 1943-7692 | 106 | 8 | SCIE | PLANT SCIENCES | 2022 | 4.5 | 17.8 | 0.3 | 2025-06-25 | 1 | 1 | blue mold; Dunggulle; first report; Penicillium expansum; Polygonatum odoratum | blue mold; Dunggulle; first report; Penicillium expansum; Polygonatum odoratum | English | 2022 | 2022-08-01 | 10.1094/pdis-11-21-2555-pdn | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | Determining the Anticancer Activity of Sphingosine Kinase Inhibitors Containing Heteroatoms in Their Tail Structure | Sphingosine kinase (SK) enzyme, a central player of sphingolipid rheostat, catalyzes the phosphorylation of sphingosine to the bioactive lipid mediator sphingosine 1 phosphate (S1P), which regulates cancer cell proliferation, migration, differentiation, and angiogenesis through its extracellular five G protein-coupled S1P receptors (S1PR(1-5)). Recently, several research studies on SK inhibitors have taken place in order use them for the development of novel anticancer-targeted therapy. In this study, we designed and synthesized analog derivatives of known SK1 inhibitors, namely RB005 and PF-543, by introducing heteroatoms at their tail structure, as well as investigated their anticancer activities and pharmacokinetic parameters in vitro. Compounds 1-20 of RB005 and PF-543 derivatives containing an aliphatic chain or a tail structure of benzenesulfonyl were synthesized. All compounds of set 1 (1-10) effectively reduced cell viability in both HT29 and HCT116 cells, whereas set 2 derivatives (11-20) showed poor anticancer effect. Compound 10, having the highest cytotoxic effect (48 h, HT29 IC50 = 6.223 mu M, HCT116 IC50 = 8.694 mu M), induced HT29 and HCT116 cell death in a concentration-dependent manner through the mitochondrial apoptotic pathway, which was demonstrated by increased annexin V-FITC level, and increased apoptotic marker cleaved caspase-3 and cleaved PARP. Compound 10 inhibited SK1 by 20%, and, thus, the S1P level decreased by 42%. Unlike the apoptosis efficacy, the SK1 inhibitory effect and selectivity of the PF-543 derivative were superior to that of the RB005 analog. As a result, compounds with an aliphatic chain tail exhibited stronger apoptotic effects. However, this ability was not proportional to the degree of SK inhibition. Compound 10 increased the protein phosphatase 2A (PP2A) activity (1.73 fold) similar to FTY720 (1.65 fold) and RB005 (1.59 fold), whereas compounds 11 and 13 had no effect on PP2A activation. Since the PP2A activity increased in compounds with an aliphatic chain tail, it can be suggested that PP2A activation has an important effect on anticancer and SK inhibitory activities. | Shrestha, Jitendra; Kim, Seong Woong; Kim, Su-Bin; Oh, Yoon Sin; Ki, Sung Hwan; Lee, Taeho; Kim, Sang-Bum; Park, Taeuk; Baek, Dong Jae; Park, Eun-Young | Mokpo Natl Univ, Coll Pharm, Yeongsan Ro, South Korea; Eulji Univ, Dept Food & Nutr, Seongnam 13135, South Korea; Chosun Univ, Coll Pharm, Gwangju 61452, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, Daegu 41566, South Korea; Daegu Gyeongbuk Med Innovat Fdn, New Drug Dev Ctr, Daegu 41061, South Korea; Daegu Gyeongbuk Med Innovat Fdn, Lab Anim Ctr, Daegu 41061, South Korea | ; Shrestha, Jitendra/KWU-2275-2024; , Do Hyang Kim/J-6575-2012 | 57200500479; 57411798200; 57217012276; 34467778200; 8346836500; 57204032003; 57196231559; 57212373985; 57200593717; 56680548000 | shresthasimon2011@gmail.com;76pey@naver.com;rlatnqls0801@naver.com;ysoh@eulji.ac.kr;shki@chosun.ac.kr;tlee@knu.ac.kr;ksb2014@dgmif.re.kr;tw3000@dgmif.re.kr;dbaek@mokpo.ac.kr;parkey@mokpo.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 1 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 0.21 | 2025-06-25 | 2 | 2 | SK inhibitor; colorectal cancer; S1P; derivative; anticancer agent; PP2A | DISCOVERY; CANCER; FTY720; POTENT | Anticancer agent; Colorectal cancer; Derivative; PP2A; S1P; SK inhibitor | English | 2022 | 2022-01 | 10.3390/pharmaceutics14010157 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Development of In Situ Microfluidic System for Preparation of Controlled Porous Microsphere for Tissue Engineering | In this study, we present an in situ microfluidic system to precisely control highly porous polycaprolactone microspheres as tissue templates for tissue engineering. The porosity of the microspheres was controlled by adjusting the flow rates of the polymer phase and the pore-generating material phase in the dispersed phase. The microfluidic flow-focusing technique was adopted to manufacture porous microspheres using a relatively highly viscous polymer solution, and the device was fabricated by conventional photolithography and PDMS casting. The fabricated in situ microfluidic system was used to precisely control the pore size of monodispersed polycaprolactone microspheres. The porous microspheres with controlled pore sizes were evaluated by culturing HDF cells on the surface of porous microspheres and injection into the subcutaneous tissue of rats. We found that the increased pore size of the microspheres improved the initial proliferation rate of HDF cells after seeding and relieved the inflammatory response after the implantation of porous microspheres in the subcutaneous tissue of rats. | Han, Ji Hwan; Kim, Chul Min; Kim, Tae-Hyun; Jin, Songwan; Kim, Gyu Man | Kyungpook Natl Univ, Sch Mech Engn, 80 Daehakro, Daegu 41566, South Korea; Gyeongsang Natl Univ, Dept Mechatron Engn, 33 Dongjin Ro, Jinju 52725, South Korea; R&D Ctr, Tissue Engn Bio Sci, 194-41 Osongsaengmyeong 1 Ro, Cheongju 28159, South Korea; Tech Univ Korea, Dept Mech Engn, 237 Sangidaehak Ro, Siheung Si 15073, South Korea | ; Kim, Chul-Min/ABI-6131-2020; Ko, Jae-Hyeon/I-4133-2019 | 58132023300; 59316640400; 58132612200; 16645779200; 55664733000 | songwan@tukorea.ac.kr;gyuman.kim@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 11 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 0.75 | 2025-06-25 | 7 | 7 | microfluidics; porous microsphere; controlled pore; cell delivery; inflammation | SCAFFOLD; SIZE | cell delivery; controlled pore; inflammation; microfluidics; porous microsphere | polycaprolactone; animal experiment; animal tissue; Article; cell assay; cell culture; controlled study; dispersion; evaluation study; flow rate; histology; human; human cell; immunohistochemistry; in vitro study; in vivo study; male; microfluidics; nonhuman; physical phase; pore size; porosity; rat; skin fibroblast; subcutaneous tissue; tissue engineering | English | 2022 | 2022-11 | 10.3390/pharmaceutics14112345 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Enhanced Micro-Channeling System via Dissolving Microneedle to Improve Transdermal Serum Delivery for Various Clinical Skincare Treatments | Topical liquid formulations, dissolving microneedles (DMNs), and microscale needles composed of biodegradable materials have been widely used for the transdermal delivery of active compounds for skincare. However, transdermal active compound delivery by topical liquid formulation application is inhibited by skin barriers, and the skincare efficacy of DMNs is restricted by the low encapsulation capacity and incomplete insertion. In this study, topical serum application via a dissolvable micro-channeling system (DMCS) was used to enhance serum delivery through micro-channels embedded with DMNs. Transdermal serum delivery was evaluated after the topical-serum-only application and combinatorial serum application by assessing the intensity of allophycocyanin (APC) loaded with the serum in the porcine skin. APC intensity was significantly higher in the skin layer at a depth of 120-270 mu m upon combinatorial serum application as compared to topical-serum-only application. In addition, the combinatorial serum application showed significantly improved efficacy in the clinical assessment of skin hydration, depigmentation, improvement of wrinkles, elasticity, dermal density, skin pores, and skin soothing without any safety issues compared to the serum-only application. The results indicate that combinatorial serum application with DMCS is a promising candidate for improving skincare treatments with optimal transdermal delivery of active compounds. | Sim, Jeeho; Gong, SeongDae; Kang, Geonwoo; Jang, Mingyu; Yang, Huisuk; Park, Jaesung; Kim, Youngchan; Lee, Hyunkyu; Jung, Hyunji; Kim, Youseong; Jeon, Chansol; Ahn, Hyeri; Kim, Minkyung; Choi, Jaibyung; Lee, Ho; Jung, Hyungil | Yonsei Univ, Dept Biotechnol, 50 Yonsei Ro, Seoul 03722, South Korea; JUVIC Inc, 208 Digital Ro 272, Seoul 08389, South Korea; Kyungpook Natl Univ, Grad Sch, Dept Mech Engn, 80 Daehak Ro, Daegu 41566, South Korea; Kyungpook Natl Univ, Sch Convergence, Dept Robot & Smart Syst Engn, 80 Daehak Ro, Daegu 41566, South Korea; Kyungpook Natl Univ, Inst Nanophoton Applicat, 80 Daehak Ro, Daegu 41566, South Korea; Kyungpook Natl Univ, Laser Applicat Ctr, 70 Dongnae Ro, Daegu 41061, South Korea | 57919024100; 57219904099; 57194446873; 56450110200; 55875528600; 57221145710; 59053232800; 58032638300; 57219904590; 57210593926; 58032809000; 57927540900; 59630520100; 58033316100; 26660670700; 9942054000 | hijung@yonsei.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 12 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 0.43 | 2025-06-25 | 4 | 4 | serum; topical application; dissolvable micro-channeling system; transdermal delivery; skin hydration; skin depigmentation; wrinkle improvement | POLYMER MICRONEEDLES; FABRICATION; PENETRATION; ADENOSINE; OINTMENT; DEVICES; ARRAYS | dissolvable micro-channeling system; serum; skin depigmentation; skin hydration; topical application; transdermal delivery; wrinkle improvement | allophycocyanin; animal experiment; animal tissue; Article; channel gating; clinical assessment; confocal laser scanning microscopy; controlled study; drug delivery system; echography; elasticity; erythema; human; human experiment; hydration; hydrogen bond; lens; melanogenesis; melanosome; nonhuman; novel object recognition test; optical coherence tomography; serum; skin defect; skin pigmentation; skin water loss; viscoelasticity; visual analog scale | English | 2022 | 2022-12 | 10.3390/pharmaceutics14122804 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Enhancing Dissolution and Oral Bioavailability of Ursodeoxycholic Acid with a Spray-Dried pH-Modified Extended Release Formulation | Ursodeoxycholate (UDCA) has low oral bioavailability and pH-dependent solubility and permeability. Thus, we developed a pH-modified extended-release formulation of UDCA using Na2CO3 as the alkalizing agent and hydroxypropyl methylcellulose (HPMC) as the release-modifying agent. The optimized pH-modified controlled-release UDCA formulation, with the UDCA:HPMC:Na2CO3 ratio of 200:600:150 (w/w/w), was prepared using a spray-drying method. Then, the formulation's solubility, dissolution, and pharmacokinetic properties were characterized. In a pH-modified extended-release formulation of UDCA, the solubility of UDCA was increased to 8 mg/mL with a sustained dissolution for 12 h. Additionally, the spray-dried formulation exhibited amorphous states without molecular interaction among UDCA, Na2CO3, and HPMC. Moreover, the plasma UDCA concentration of the formulation maintained a higher UDCA concentration for up to 48 h than that of UDCA itself or the non-extended-release UDCA formulation. Consequently, the formulation significantly increased the AUC compared to UDCA or the non-extended-release UDCA formulation in rats. In conclusion, we have improved UDCA's solubility and dissolution profile by preparing a pH-modified extended-release formulation with the UDCA:HPMC:Na2CO3 ratio of 200:600:150 (w/w/w), which effectively increased the oral bioavailability of UDCA by 251% in rats. | Lee, Jaehyeok; Lee, Chul Haeng; Lee, Jong-Geon; Jeon, So Yeon; Choi, Min-Koo; Song, Im-Sook | Kyungpook Natl Univ, BK21 FOUR Community Based Intelligent Novel Drug, Vessel Organ Interact Res Ctr VOICE, Res Inst Pharmaceut Sci,Coll Pharm, Daegu 41566, South Korea; Dankook Univ, Coll Pharm, Cheonan Si 31116, South Korea | 57219980183; 57219051827; 57704944800; 57226815842; 8695781400; 7201564500 | here0723@gmail.com;hang1130@naver.com;jkl7604@naver.com;ojsw97@naver.com;minkoochoi@dankook.ac.kr;isssong@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 5 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 0.64 | 2025-06-25 | 6 | 6 | ursodeoxycholate (UDCA); oral bioavailability; pH-modified extended release formulation; spray-drying method | BILE-ACIDS; INTESTINAL-ABSORPTION; PHOSPHOLIPID COMPLEX; IN-VITRO; LIVER; IMPROVEMENT; SOLUBILITY; DRUG; HEPATOCYTES; CHOLESTASIS | oral bioavailability; pH-modified extended release formulation; spray-drying method; ursodeoxycholate (UDCA) | hydroxypropylmethylcellulose; ursodeoxycholic acid; animal experiment; area under the curve; Article; controlled study; drug bioavailability; drug blood level; drug formulation; drug half life; drug penetration; drug solubility; drug structure; male; mean residence time; molecular interaction; nonhuman; pH measurement; rat; spray drying; sustained drug release; time to maximum plasma concentration | English | 2022 | 2022-05 | 10.3390/pharmaceutics14051037 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Epoxinnamide: An Epoxy Cinnamoyl-Containing Nonribosomal Peptide from an Intertidal Mudflat-Derived Streptomyces sp. | Cinnamoyl-containing nonribosomal peptides (CCNPs) form a unique family of actinobacterial secondary metabolites and display various biological activities. A new CCNP named epoxinnamide (1) was discovered from intertidal mudflat-derived Streptomyces sp. OID44. The structure of 1 was determined by the analysis of one-dimensional (1D) and two-dimensional (2D) nuclear magnetic resonance (NMR) data along with a mass spectrum. The absolute configuration of 1 was assigned by the combination of advanced Marfey's method, (3)J(HH) and rotating-frame overhauser effect spectroscopy (ROESY) analysis, DP4 calculation, and genomic analysis. The putative biosynthetic pathway of epoxinnamide (1) was identified through the whole-genome sequencing of Streptomyces sp. OID44. In particular, the thioesterase domain in the nonribosomal peptide synthetase (NRPS) biosynthetic gene cluster was proposed as a bifunctional enzyme, which catalyzes both epimerization and macrocyclization. Epoxinnamide (1) induced quinone reductase (QR) activity in murine Hepa-1c1c7 cells by 1.6-fold at 5 mu M. It also exhibited effective antiangiogenesis activity in human umbilical vein endothelial cells (IC50 = 13.4 mu M). | Kang, Sangwook; Han, Jaeho; Jang, Sung Chul; An, Joon Soo; Kang, Ilnam; Kwon, Yun; Nam, Sang-Jip; Shim, Sang Hee; Cho, Jang-Cheon; Lee, Sang Kook; Oh, Dong-Chan | Seoul Natl Univ, Coll Pharm, Nat Prod Res Inst, Seoul 08826, South Korea; Inha Univ, Dept Biol Sci, Incheon 22212, South Korea; Kyungpook Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Daegu 41566, South Korea; Ewha Womans Univ, Dept Chem & Nanosci, Seoul 03760, South Korea | An, Joon Soo/NOF-1416-2025; Lee, Soohyeon/AAX-9843-2020; Shim, Sang-Hee/A-9051-2012; Cho, Jang-Cheon/B-4676-2013 | 57827837800; 57223649995; 57554826900; 57208526859; 7203062761; 56156932300; 57208839798; 59125093800; 7403534470; 36067620500; 8707854600 | ksw1657@snu.ac.kr;gh03292@snu.ac.kr;tobok95@snu.ac.kr;ahnjunsoo@snu.ac.kr;ikang@inha.ac.kr;yunkwon@knu.ac.kr;sjnam@ewha.ac.kr;sangheeshim@snu.ac.kr;chojc@inha.ac.kr;sklee61@snu.ac.kr;dongchanoh@snu.ac.kr; | MARINE DRUGS | MAR DRUGS | 1660-3397 | 20 | 7 | SCIE | CHEMISTRY, MEDICINAL;PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 1.15 | 2025-06-25 | 10 | 10 | cinnamoyl-containing nonribosomal peptide; Streptomyces; biosynthetic gene cluster; bifunctional thioesterase; quinone reductase; angiogenesis | BIOSYNTHETIC GENE-CLUSTER; A-C; GUT BACTERIUM; POLYKETIDE; IDENTIFICATION; DISCOVERY; WS9326A; CYCLODEPSIPEPTIDE; STEREOCHEMISTRY; COPRISAMIDES | angiogenesis; bifunctional thioesterase; biosynthetic gene cluster; cinnamoyl-containing nonribosomal peptide; quinone reductase; Streptomyces | Animals; Biosynthetic Pathways; Endothelial Cells; Humans; Mice; Multigene Family; Peptide Synthases; Peptides; Streptomyces; epoxinnamide; peptide derivative; reduced nicotinamide adenine dinucleotide (phosphate) dehydrogenase (quinone); unclassified drug; peptide; peptide synthase; antiangiogenic activity; Article; biosynthesis; catalysis; controlled study; drug structure; enzyme activity; enzyme structure; epimerization; gene cluster; genomics; Hepa-1c1c7 cell line; human; human cell; IC50; mass spectrometry; nonhuman; nuclear magnetic resonance; Streptomyces; structure analysis; umbilical vein endothelial cell; whole genome sequencing; animal; endothelium cell; genetics; metabolism; mouse; multigene family; Streptomyces | English | 2022 | 2022-07 | 10.3390/md20070455 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Editorial Material | First Report of Colletotrichum fioriniae Causing Anthracnose on the Fruit of Omija (Schisandra) in South Korea | Kim, Jaewon; Hassan, Oliul; Kim, Kyung-Min; Chang, Taehyun | Kyungpook Natl Univ, Coll Ecol & Environm Sci, Sch Ecol & Environm Syst, Sangju 37224, Gyeongsangbuk D, South Korea; Kyungpook Natl Univ, Coll Agr & Life Sci, Sch Appl BioSci, Daegu 41566, South Korea | Hassan, Oliul/AEB-6678-2022; Chang, Taehyun/S-1364-2019; Kim, Kyung-Min Kim/C-7007-2014 | 57967050700; 12762464400; 34868260300; 55301101700 | thchang@knu.ac.kr; | PLANT DISEASE | PLANT DIS | 0191-2917 | 1943-7692 | 106 | 11 | SCIE | PLANT SCIENCES | 2022 | 4.5 | 17.8 | 1.19 | 2025-06-25 | 3 | 4 | anthracnose; Colletotrichum fioriniae; five-flavor-fruit; molecular analysis | anthracnose; Colletotrichum fioriniae; five-flavor-fruit; molecular analysis | English | 2022 | 2022-11-01 | 10.1094/pdis-03-22-0471-pdn | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Editorial Material | First Report of Squash leaf curl China virus Associated with Mosaic and Mild Leaf Curl Disease of Pumpkin in Bangladesh | Vo, Thuy T.; Eui-Joon, Kil; Chairina, Fadhila; Lal, Aamir; Ho, Phuong T.; Lee, Kyeong-Yeoll; Jahan, S. M. Hemayet; Lee, Sukchan | Sungkyunkwan Univ, Dept Integrat Biotechnol, Suwon, South Korea; Andong Natl Univ, Dept Plant Med, Andong, South Korea; Kyungpook Natl Univ, Inst Plant Med, Daegu, South Korea; Patuakhali Sci & Technol Univ, Dept Entomol, Dumki, Patuakhali, Bangladesh | Vo, Thuy/JJC-2540-2023; Kil, Eui-Joon/AAZ-9823-2020; Jahan, Prof. Dr. Hemayet/O-1760-2019; Kil, Eui-Joon/AFE-1359-2022 | 57215688330; 26534336800; 57915763400; 57204936481; 57215691568; 57217153096; 55329416200; 57213176749 | viruskil@anu.ac.kr;hemayet_pstu@yahoo.com;cell4u@skku.edu; | PLANT DISEASE | PLANT DIS | 0191-2917 | 1943-7692 | 106 | 10 | SCIE | PLANT SCIENCES | 2022 | 4.5 | 17.8 | 0.59 | 2025-06-25 | 1 | 2 | begomovirus detection; pumpkin; squash leaf curl China virus | PCR-MEDIATED AMPLIFICATION; UNIVERSAL PRIMERS; DNA-BETA | begomovirus detection; pumpkin; squash leaf curl China virus | English | 2022 | 2022-10-03 | 10.1094/pdis-12-21-2758-pdn | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Formulation of a Gastroretentive In Situ Oral Gel Containing Metformin HCl Based on DoE | A gastroretentive in situ oral gel containing metformin hydrochloride (Met HCl) was prepared based on sodium alginate (Sod ALG), calcium carbonate, and hydroxyethylcellulose (HEC). The optimal composition of the formulation was explored based on the design of experiments (DoE). First, a 3(2) full factorial design was used for formulation E1 to determine proper composition of Sod ALG and calcium carbonate. Second, a circumscribed central composite design was employed to add HEC as a thickening agent (formulation E2). The dissolution rates at 15, 30, 60, 120, and 240 min were used as responses. Partial least squares regression analysis indicated the effect of each component in delaying the release of Met HCl in the oral gel formulation. The optimized formulation E2-08 consisting of 1.88% Sod ALG, 0.63% HEC, and 1.00% calcium carbonate and two more formulations, E2-10 and E2-12 conformed to USP monograph for extended release. Other physicochemical properties, including floating lag time and duration, viscosity, and pH, measured for each batch and FT-IR spectrometry analysis showed no unexpected interaction between Met HCl and excipients. The current study suggests the potential use of a gastroretentive in situ oral gel for Met HCl helping patient compliance. This study highlights that a systematic approach based on DoE allows the formulation optimization. | Kim, Jong Hee; Song, Seung Hyun; Joo, Sang Hoon; Park, Gyu Hwan; Weon, Kwon-Yeon | Daegu Catholic Univ, Coll Pharm, Gyongsan 38430, South Korea; Kyungpook Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Daegu 41566, South Korea | ; Joo, Sang/B-4116-2008 | 57902074700; 57902074800; 55550907200; 9939639300; 6507232168 | park014@knu.ac.kr;weonky@cu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 9 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 0.64 | 2025-06-25 | 5 | 7 | metformin HCl; in situ oral gel; experimental design; formulation; sustained release (SR) | DRUG-DELIVERY SYSTEM; INTESTINAL PERMEABILITY; SUSTAINED-RELEASE; VITRO; PERFORMANCE; ABSORPTION; CAPSULE | experimental design; formulation; in situ oral gel; metformin HCl; sustained release (SR) | alginic acid; calcium carbonate; hydroxyethylcellulose; metformin; Article; central composite design; chemical composition; controlled drug release; controlled study; drug formulation; drug solubility; Fourier transform infrared spectroscopy; physical chemistry; sustained drug release; viscosity | English | 2022 | 2022-09 | 10.3390/pharmaceutics14091777 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Glioblastoma-Derived Exosomes as Nanopharmaceutics for Improved Glioma Treatment | The use of cancer-derived exosomes has been studied in several cancer types, but the cancer-targeting efficacy of glioma-derived exosomes has not been investigated in depth for malignant glioblastoma (GBM) cells. In this study, exosomes were derived from U87MG human glioblastoma cells, and selumetinib, a new anticancer drug, was loaded into the exosomes. We observed the tropism of GBM-derived exosomes in vitro and in vivo. We found that the tropism of GBM-derived exosomes is in contrast to the behavior of non-exosome-enveloped drugs and non-GBM-specific exosomes in vitro and in vivo in an animal GBM model. We found that the tropism exhibited by GBM-derived exosomes can be utilized to shuttle selumetinib, with no specific targeting moiety, to GBM tumor sites. Therefore, our findings indicated that GBM-derived exosomes loaded with selumetinib had a specific antitumor effect on U87MG cells and were non-toxic to normal brain cells. These exosomes offer improved therapeutic prospects for glioblastoma therapy. | Lee, Hyeji; Bae, Kanghye; Baek, Ah-Rum; Kwon, Eun-Bin; Kim, Yeoun-Hee; Nam, Sung-Wook; Lee, Gang Ho; Chang, Yongmin | Kyungpook Natl Univ, Sch Med, Dept Med Sci, Daegu 41944, South Korea; Kyungpook Natl Univ, Inst Biomed Engn Res, Daegu 41405, South Korea; Korea Inst Oriental Med, Korean Med KM Applicat Ctr, Daegu 41062, South Korea; Etnova Therapeut Corp, R&D Ctr, 124 Sagimakgol Ro, Seongnam Si 13207, South Korea; Kyungpook Natl Univ, Sch Med, Dept Mol Med, Daegu 41944, South Korea; Kyungpook Natl Univ, Coll Nat Sci, Dept Chem, Daegu 41566, South Korea | Nam, Sung-Wook/V-5519-2019 | 57654051800; 57695407900; 57194601711; 57217187483; 57576538700; 16167127700; 7404851841; 7501840633 | pba04052@naver.com;hjbkh980708@naver.com;baxun@naver.com;wrld2931@kiom.re.kr;yhkim@etnova.co.kr;nams@knu.ac.kr;ghlee@knu.ac.kr;ychang@knu.ac.kr; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 5 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 3.52 | 2025-06-25 | 32 | 34 | glioblastoma (GBM); cancer-derived exosome; anticancer effect; cancer-targeting effect | EXTRACELLULAR VESICLES; SELUMETINIB AZD6244; CANCER; DELIVERY; THERAPY; CELLS; ARRY-142886; INHIBITOR | anticancer effect; cancer‐derived exosome; cancer‐targeting effect; glioblastoma (GBM) | antineoplastic agent; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; protein bcl 2; selumetinib; A-549 cell line; animal cell; animal experiment; animal model; animal tissue; apoptosis; Article; astrocyte; cell culture; cell viability; centrifugation; chemiluminescence immunoassay; cytotoxicity; electroporation; exosome; exsanguination; flow cytometry; fluorescence activated cell sorting; fluorescence intensity; fluorescence microscopy; glioblastoma; glioma; histology; immunofluorescence; immunohistochemistry; liver function; liver toxicity; male; mouse; nanopharmaceutics; nephrotoxicity; nonhuman; protein expression; radioimmunoprecipitation; transmission electron microscopy; tropism; tumor microenvironment; tumor volume; U-87MG ATCC cell line; Western blotting | English | 2022 | 2022-05 | 10.3390/pharmaceutics14051002 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | High Incidence of Intracerebral Hemorrhaging Associated with the Application of Low-Intensity Focused Ultrasound Following Acute Cerebrovascular Injury by Intracortical Injection | Low-intensity transcranial focused ultrasound (FUS) has gained momentum as a non-/minimally-invasive modality that facilitates the delivery of various pharmaceutical agents to the brain. With the additional ability to modulate regional brain tissue excitability, FUS is anticipated to confer potential neurotherapeutic applications whereby a deeper insight of its safety is warranted. We investigated the effects of FUS applied to the rat brain (Sprague-Dawley) shortly after an intracortical injection of fluorescent interstitial solutes, a widely used convection-enhanced delivery technique that directly (i.e., bypassing the blood-brain-barrier (BBB)) introduces drugs or interstitial tracers to the brain parenchyma. Texas Red ovalbumin (OA) and fluorescein isothiocyanate-dextran (FITC-d) were used as the interstitial tracers. Rats that did not receive sonication showed an expected interstitial distribution of OA and FITC-d around the injection site, with a wider volume distribution of OA (21.8 +/- 4.0 mu L) compared to that of FITC-d (7.8 +/- 2.7 mu L). Remarkably, nearly half of the rats exposed to the FUS developed intracerebral hemorrhaging (ICH), with a significantly higher volume of bleeding compared to a minor red blood cell extravasation from the animals that were not exposed to sonication. This finding suggests that the local cerebrovascular injury inflicted by the micro-injection was further exacerbated by the application of sonication, particularly during the acute stage of injury. Smaller tracer volume distributions and weaker fluorescent intensities, compared to the unsonicated animals, were observed for the sonicated rats that did not manifest hemorrhaging, which may indicate an enhanced degree of clearance of the injected tracers. Our results call for careful safety precautions when ultrasound sonication is desired among groups under elevated risks associated with a weakened or damaged vascular integrity. | Kim, Evgenii; Van Reet, Jared; Kim, Hyun-Chul; Kowsari, Kavin; Yoo, Seung-Schik | Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; Kyungpook Natl Univ, Dept Artificial Intelligence, Daegu 37224, South Korea; MIT, Dept Mech Engn, Cambridge, MA 02139 USA | 59845978800; 57823770600; 57194876917; 55943178100; 7401970708 | yoo@bwh.harvard.edu; | PHARMACEUTICS | PHARMACEUTICS | 1999-4923 | 14 | 10 | SCIE | PHARMACOLOGY & PHARMACY | 2022 | 5.4 | 17.8 | 0.32 | 2025-06-25 | 3 | 3 | brain; ultrasound; drug delivery; interstitial tracers; hemorrhaging; glymphatic | CONVECTION-ENHANCED DELIVERY; BLOOD-BRAIN-BARRIER; GLIOBLASTOMA-MULTIFORME; MONOCLONAL-ANTIBODY; DRUG-DELIVERY; ANIMAL-MODELS; IN-VIVO; STIMULATION; GLIOMA; STROKE | brain; drug delivery; glymphatic; hemorrhaging; interstitial tracers; ultrasound | fluorescein isothiocyanate dextran; ovalbumin; animal experiment; animal model; Article; brain; brain hemorrhage; cerebrovascular accident; controlled study; drug clearance; drug delivery system; extravasation; fluorescence; glymphatic system; incidence; low intensity focused ultrasound; male; nonhuman; rat | English | 2022 | 2022-10 | 10.3390/pharmaceutics14102120 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: